JP7820822B2 - 臓器損傷を治療するための安定なジグリセリド乳剤および方法 - Google Patents

臓器損傷を治療するための安定なジグリセリド乳剤および方法

Info

Publication number
JP7820822B2
JP7820822B2 JP2022562912A JP2022562912A JP7820822B2 JP 7820822 B2 JP7820822 B2 JP 7820822B2 JP 2022562912 A JP2022562912 A JP 2022562912A JP 2022562912 A JP2022562912 A JP 2022562912A JP 7820822 B2 JP7820822 B2 JP 7820822B2
Authority
JP
Japan
Prior art keywords
composition
emulsion
patient
stroke
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022562912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521917A5 (https=
JP2023521917A (ja
Inventor
ジェー． デッケルバウム，リチャード
リズ チャン，チュチュン
ジルポリ，ヒルデ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of JP2023521917A publication Critical patent/JP2023521917A/ja
Publication of JP2023521917A5 publication Critical patent/JP2023521917A5/ja
Application granted granted Critical
Publication of JP7820822B2 publication Critical patent/JP7820822B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022562912A 2020-04-15 2021-04-15 臓器損傷を治療するための安定なジグリセリド乳剤および方法 Active JP7820822B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063010364P 2020-04-15 2020-04-15
US63/010,364 2020-04-15
PCT/US2021/027411 WO2021211796A1 (en) 2020-04-15 2021-04-15 Stable diglyceride emulsions and methods for treating organ injury

Publications (3)

Publication Number Publication Date
JP2023521917A JP2023521917A (ja) 2023-05-25
JP2023521917A5 JP2023521917A5 (https=) 2024-04-25
JP7820822B2 true JP7820822B2 (ja) 2026-02-26

Family

ID=78084595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562912A Active JP7820822B2 (ja) 2020-04-15 2021-04-15 臓器損傷を治療するための安定なジグリセリド乳剤および方法

Country Status (8)

Country Link
US (1) US20230190693A1 (https=)
EP (1) EP4135684B1 (https=)
JP (1) JP7820822B2 (https=)
CN (1) CN115996711A (https=)
CA (1) CA3175453A1 (https=)
DK (1) DK4135684T3 (https=)
ES (1) ES3041336T3 (https=)
WO (1) WO2021211796A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112513235B (zh) 2018-06-05 2023-12-01 帝斯曼知识产权资产管理有限公司 用于生产甘油二酯的方法
CN117241816A (zh) * 2020-12-07 2023-12-15 纽约市哥伦比亚大学理事会 用于新生儿缺氧缺血性脑病的神经保护的组合物和方法
WO2025146681A1 (en) * 2024-01-01 2025-07-10 Hadasit Medical Research Services & Development Ltd. Pro-nano-emulsions comprising omega 3 and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410181B2 (en) 2006-09-19 2013-04-02 The Trustees Of Columbia University In The City Of New York Omega-3 diglyceride emulsions
JP2014516249A (ja) 2011-04-04 2014-07-10 ディーエスエム アイピー アセッツ ビー．ブイ． 多価不飽和脂肪酸を含む水中油型乳剤およびその製造方法
JP2015508791A (ja) 2012-02-29 2015-03-23 ビー．ブラウン メルズンゲン アーゲーＢ．Ｂｒａｕｎ Ｍｅｌｓｕｎｇｅｎ Ａｇ オキアミリン脂質を含むホルモン含有乳剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
KR102424837B1 (ko) * 2014-09-19 2022-07-25 헤론 테라퓨틱스 인코포레이티드 아프레피탄트의 에멀젼 제형

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410181B2 (en) 2006-09-19 2013-04-02 The Trustees Of Columbia University In The City Of New York Omega-3 diglyceride emulsions
JP2014516249A (ja) 2011-04-04 2014-07-10 ディーエスエム アイピー アセッツ ビー．ブイ． 多価不飽和脂肪酸を含む水中油型乳剤およびその製造方法
JP2015508791A (ja) 2012-02-29 2015-03-23 ビー．ブラウン メルズンゲン アーゲーＢ．Ｂｒａｕｎ Ｍｅｌｓｕｎｇｅｎ Ａｇ オキアミリン脂質を含むホルモン含有乳剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sergey M. Melnikov et al.，"Colloidal emulsion based delivery systems for steroid glycosides"，Journal of Functional Foods，2017年，Vol.28，p.90-95，DOI: 10.1016/j.jff.2016.11.014

Also Published As

Publication number Publication date
EP4135684B1 (en) 2025-06-18
WO2021211796A1 (en) 2021-10-21
EP4135684A1 (en) 2023-02-22
CA3175453A1 (en) 2021-10-21
EP4135684A4 (en) 2024-05-01
CN115996711A (zh) 2023-04-21
ES3041336T3 (en) 2025-11-11
JP2023521917A (ja) 2023-05-25
US20230190693A1 (en) 2023-06-22
DK4135684T3 (da) 2025-09-15

Similar Documents

Publication Publication Date Title
Hippalgaonkar et al. Injectable lipid emulsions—advancements, opportunities and challenges
RU2678319C2 (ru) Гормонсодержащая эмульсия
US9084801B2 (en) Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
US8410181B2 (en) Omega-3 diglyceride emulsions
JP7820822B2 (ja) 臓器損傷を治療するための安定なジグリセリド乳剤および方法
CN105939705B (zh) 用于肠胃外给药的包含epa甘油三酯和dha甘油三酯的组合物
PT2720701T (pt) Aplicação terapêutica de óleo de krill parentérico
EP3373909A1 (en) Vitamin k-enriched lipid emulsion formulations for the treatment of pharma toxicity
US9801846B2 (en) Composition comprising EPA and DHA ethylester for parenteral administration
US8895074B2 (en) Therapeutic application of parenteral krill oil
JPS61221114A (ja) 脂肪乳剤
CN110312509A (zh) 使用epa和dha的肝病治疗的长期功效
JPH04108732A (ja) Ｐａｆ拮抗剤含有脂肪乳剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250422

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260205

R150 Certificate of patent or registration of utility model

Ref document number: 7820822

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150